Objectives: Gold nanoparticles have become promising vectors for cancer diagnosis and treatment. The present study investigates the effect of Bortezomib (BTZ), a proteasome inhibitor, conjugated with pegylated gold nanoparticles (PEGAuNPs) in pancreatic and lung cancer cells. Methods: Synthesized gold nanoparticles (PEGAuNPs) were conjugated with bortezomib antitumor drug. We investigated the cytotoxicity induced by Bortezomib conjugated with functionalized gold nanoparticles in vitro, in the human pancreatic (S2-013) and lung (A549) cancer cell lines. Results: We found an efficient of conjugation of BTZ with PEGAuNPs. In vitro assays showed that after 72 hours' incubation with PEGAuNPs-BTZ cancer cells revealed alterations in morphology; also for S2-013 and A549 cancer cells, the IC50 value of free BTZ is respectively 1.5 and 4.3 times higher than the IC50 value of PEGAuNPs-BTZ. Furthermore, for TERT-HPNE, the IC50 value is around 63 times lower for free BTZ than to the conjugated nanovehicle. Cell growth inhibition results showed a remarkable enhancement in the effect of BTZ when conjugated with AuNPs. Conclusions: Our findings showed that conjugation with PEGAuNPs enhance the BTZ growth-inhibition effect on human cancer cells (S2-013 and A549) and decreases its toxicity against normal cells (TERT-HPNE).
Introduction
The research on nanotechnology-based delivery carriers opened new promising strategies for targeted drug delivery and diagnosis of various tumours [1] . Recently, the innovation on drug nanocarriers was focused on the challenging limitations associated with multidrug resistance (MDR) and dose-toxicity [2] . The undesired effects of conventional chemotherapy and radiotherapy associated with unfavorable drug pharmacokinetics and pharmacodynamics fostered the design and testing of novel delivery systems for a myriad of antitumor drugs [3] [4] [5] . Compared to chemotherapeutic agents, nanocarriers can improve tumour specificity and intensify drug efficacy [4] . Nanovehicles can passively target solid tumours due to the enhanced permeability and retention (EPR) effect in these neoplastic tissues [2, 3] . They are able to be internalized in different cell cycle phases [6] .
Amongst these drug delivery systems (DDS), gold nanoparticles are a novel and promising carrier due to the enhanced stability and reduced toxicity [7] [8] [9] .
Colloidal gold nanoparticles (AuNPs) have been extensively studied for different therapeutic applications [3, 10, 11] . They have been distinguished because of their optical properties as a high surface area to volume ratio exhibiting high selectivity and chemical reactivity [12] [13] [14] . They present high biocompatibility, stability and easy conjugation, non-toxicity and good uptake on human cells [15, 16] . Recently, gold-based nanoparticles have been used to develop new agents as cancer imaging probes [17, 18] , as agents to enhance radiation therapy [19] [20] [21] [22] and as drug delivery systems for cancer treatment [23] [24] [25] . Several studies reported that AuNPs in combination with chemotherapy and radiotherapy improve therapy efficacy in different cancer types, including pancreatic and human lung cancers [15, [26] [27] [28] .
Gold nanoparticles are reported to increase the drug toxicity compared to free drug [4, 15, 23, 29, 30] . This fact occurs by passive targeting through EPR effect [31] . Pegylation of AuNPs (PEGAuNPs) has been shown to increase the circulation time by reducing the protein absorption and reticuloendothelial system uptakeopsonisation, mechanisms associated to low bioavailability [22, [32] [33] [34] .
Bortezomib (BTZ), a reversible inhibitor of the 26S proteasome, indicated to treat patients with multiple myeloma, is known for its antiproliferative, proapoptotic, antiangiogenic and antitumour activities [35] . It inhibits the regulation of basic cellular functions as cell-division cycle, proliferation, differentiation and apoptosis [36] . It is a boronic acid dipeptide reported in preclinical studies with antitumor activity in xenograft models of multiple myeloma, adult T-cell leukemia, cancer of lung, breast, prostate, pancreas, head and neck, colon and melanoma [22, 37, 38] . Nawrocki et al. reported that BTZ sensitizes pancreatic cancer cells enhancing the anticancer activity of cisplatin [38] . More recently a phase II preclinical studies indicated a synergy of the BTZ combined with gemcitabine/carboplatin promising for advanced non-small lung cancer [39] .
Herein, the role and effect of the conjugation of BTZ with PEGAuNPs for drug delivery on cancer cells were investigated in human pancreatic (S2-013) and lung cancer cells (A549). The release efficiencies were analyzed. The cellular internalization of nanoparticles was visualized and the cellular morphology was assessed. The effect of the conjugation of BTZ with PEGAuNPs on cell growth was assessed on S2-013, A549
and TERT-HPNE cell lines.
Materials and methods

Chemicals
Bortezomib (VELCADE) was purchased from Selleck Chemicals LLC (USA); fetal bovine serum (FBS), phosphate buffered saline (PBS), trypsin, Dulbecco's modified Eagle's medium (DMEM) was obtained from Invitrogen Co. (Scotland, UK). Acetic acid, dimethyl sulfoxide (DMSO), sulforhodamine B (SRB), trypan blue, trisodium citrate dihydrate and tetrachloroauric (III) acid (HAuCl4; 99.99% trace metals basis, 30 wt % in dilute HCl) were purchased from Sigma-Aldrich (Germany). Tricloroacetic acid (TCA) and Tris buffer were acquired from Merck (Darmstadt, Germany). a-thiol-w-carboxyl (polyethylene glycol) (HS-PEG-COOH; molecular weight 394.57 Da) was purchased from Prochimia (Poland).
Synthesis of pegylated gold nanoparticles
AuNPs were synthesized by the reduction of tetrachloroauric acid (HAuCl4) with trisodium citrate -Turkevitch method [40, 41] . HAuCl4 aqueous solution was heated to slight boiling and trisodium citrate was added for 15 min. Then, AuNPs were pegylated (PEGAuNPs) with thiolated poly(ethylene glycol) carboxylic acid (PEG) layer, with a molar ratio 1:1,000, respectively. The resultant solution was centrifuged at 12,000 × g during 10 min to remove the unbound PEG molecules. The concentration of the PEGAuNPs, determined by the LambertBeer Law assuming the molar absorptivity of the AuNPs plasmon resonance band at 526 nm being 2.33x10 8 M -1 cm -1 , was 15.08 nM.
Conjugation of bortezomib to PEGAuNPs, PEGAuNPs-BTZ
For the conjugation of bortezomib (BTZ) to pegylated gold nanoparticles, the EDC/NHSS-mediated amine coupling reaction was followed [28] . The molar ratio PEGAuNPs:Bortezomib is 1:1540. The solution was stirred at room temperature for 1 h. The final solution was centrifuged at 12,000 x g during 10 min to remove the unbound antitumour drug.
Dynamic light scattering and electrophoretic mobility measurements
Size distribution and zeta potential of the nanoparticles was analyzed by dynamic light scattering (DLS) and laser Doppler velocimetry, respectively, by a Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK), at 25 ºC. Size measurements were performed at a scattering angle of 173 in a 12 mm square polystyrene cuvette (Sarstedt, Germany). The zeta potential was obtained by using a disposable capillary cell (DTS 1060, Malvern).
UV-VIS spectroscopy
The UV-VIS absorption spectra of the PEGAuNPs and PEGAuNPs-BTZ were measured in a 1 cm quartz cuvette at room temperature using a Shimadzu UV-1700 PharmaSpec spectrophotometer.
Attenuated Total Reflectance-Fourier Transform Infrared Spectroscopy (ATR-FTIR)
The PEGAuNPs-BTZ, PEGAuNPs and BTZ solutions were analysed and ATR-FTIR spectra were recorded with an ALPHA FTIR Spectrometer (Bruker) in the spectral range 4,000-400 cm −1 , resolution of 4 cm −1 and 64 scans, at room temperature.
Assay of 20S Proteasome Activity
BTZ activity was studied with 20S proteasome as described in the 20S proteasome assay kit-BML-AK740
(Enzo Life Sciences). It was performed a fluorescence standard curve of BTZ for concentrations between 20 nM and 2.5 µM.
Incubation assays with supernatants of PEGAuNPs-BTZ were performed at 37 ºC, during 50 min. BTZ activity was monitored as the reaction substrate's fluorescence emission (excitation at 360 nm, emission at 485 nm) using a microplate reader (PowerWave HT Microplate Spectrophotometer, BioTek), in order to determine the encapsulation efficiency of BTZ.
In vitro drug release studies
The drug release study of PEGAuNPs-BTZ was carried out at 37 ºC by dialysis using a regenerated cellulose membrane with an initial BTZ concentration of 17 μM, respectively. The solutions were incubated in 6 mL of PBS 0.01 M, with constant magnetic stirring. The BTZ concentration of the dialysate buffer was analyzed with time using spectrophotometric analysis at 270 nm (the concentration is under the limit of detection of the Shimadzu UV-1700 PharmaSpec spectrophotometer).
Cell lines
The pancreatic cell lines S2-013 (well differentiated tubular adenocarcinoma and moderately metastatic subline cloned from the human pancreatic tumor cell line SUIT-2) and hTERT-HPNE (immortalized human pancreatic duct epithelial cell line) were kindly provided by Prof. M. A. Hollingsworth (Eppley Institute for Research in Cancer and Allied Diseases, UNMC, Omaha, NE, USA). Adherent cell cultures were maintained in DMEM with 10% heat-inactivated FBS at 37 ºC in a humidified atmosphere of 5% CO2 incubator.
The adenocarcinoma human lung cancer cell line A549 was kindly provided by Dr George DD Jones (University of Leicester, UK). A549 cells were grown as a monolayer in RPMI 1640 media with 10% heatinactivated FBS at 37 ºC in a humidified atmosphere of 5% CO2.
Cellular imaging studies
Imaging experiments were performed with the S2-013 and A549 cells. To evaluate the influence of nanoparticle surface on the morphology in the cells, the control untreated cells were also imaged. Different areas were analyzed and at least three images were acquired for each type of cell.
Evaluation of in vitro cytotoxicity
The concentrations of PEGAuNPs-BTZ, PEGAuNPs and BTZ that inhibit cell survival in 50% (IC50) and cell growth in 50% (GI50) were determined using the SRB assay, as previously [15] . Briefly, the S2-013, hTERT-HPNE and A549 cells were seeded in 96-well plates (1,000 cells per well) under normal conditions (5% CO2 humidified atmosphere at 37 ºC) and allowed to adhere for 20-24 h. The cells were then treated for 72 h with BTZ, PEGAuNPs or PEGAuNPs-BTZ at concentrations ranging between 0.001 and 2.920 µM BTZ. Following this incubation period, the cells were fixed with 10% TCA for 1 h on ice, washed and stained with 0.4% SRB dye for 30 min. The cells were then washed repeatedly with 1% acetic acid to remove unbound dye. The protein-bound stain was solubilized with 10 mM Tris solution. The SRB absorbance was measured at 560 nm using the PowerWave microplate reader and IC50 and GI50 values determined.
Statistical analysis
At least three independent experiments were performed for each assay. Statistical significance (p < 0.05) was determined by the Student's t-Test. The stability of PEGAuNPs-BTZ for 72 hours was evaluated in phosphate buffer solution (pH 7.4) at 37 ºC, which simulates the physiological conditions ( Figure 3 ).
It is observed that BTZ has an initial delay over the first hours. After this, Figure 3 indicates the slow and controlled release of the drug. The conjugated PEGAuNPs release about 30 % of the BTZ for 72 hours. Also, for the same period of time, all amount of BTZ free without PEGAuNP presence was released. The PEGAuNPs exhibit a high controlled release of BTZ, with the release rate measured to be around 3 times lower than that of free BTZ.
To investigate the morphology of cancer cells -S2-013 and A549 cells, cancer cells were incubated for 72 hours in the presence of PEGAuNPs-BTZ. Confocal microscopy images confirm that the internalization to the cytoplasm corresponded to significant modifications on cells appearance (size and morphology) (Figure 4 ).
The nuclei of the cells are visualized with DAPI staining. It was observed the intracellular accumulation of nanocarriers, clearly encompassing the acidified membrane compartments in cytoplasm of S2-013 and A549
( Figure 4B and Figure 4E ). Comparing Figure 4B and Figure 4E to Figure 4C and Figure 4F (Table 2) , which could be explained by the increasing of the drug efficiency on suspension on S2-013 and A549.
On TERT-HPNE, the opposite effect is verified which might be due to protection of drug by PEGAuNPs. The BTZ concentrations inhibiting cell growth in 50 % (GI50 values) were around 0.0023 ± 0.0007 µM and 0.0054 ± 0.0006 µM for S2-013 and A549, respectively ( Table 2 ). For TERT-HPNEs, GI50 value is 0.0535 ± 0.0020 µM. These results suggest that PEGAuNPs-BTZ show higher toxicity effect on cancer cells in comparison with normal cells. The effectiveness of PEGAuNPs-BTZ in targeting cancer cells was observed on cell growth of S2-013 and A549 (Table 2 ).
Conclusions
In summary, this work reports the preparation of bortezomib-conjugated gold nanoparticles for cancer therapy.
The results suggested that PEGAuNPs-BTZ has a better potential than free BTZ on cancer cell growthinhibition. More important, our present data indicated that it is possible to reduce the PEGAuNPs-BTZ concentration 4.3 and 1.5 times to have the same effect as that of the free drug (BTZ) for A549 and S2-013 cells, respectively. By other hand in TERT-HPNE cells, it is necessary to increase around 63 times the concentration of PEGAuNPs-BTZ to have the same effect that free drug induces.
To have a better understanding of this novel drug conjugated PEGAuNPs, it is envisaged to test the drug delivery system in other cancer cell lines (colon, prostate, breast) foreseeing in vivo studies. Table 2 Half maximal inhibitory concentration (IC50) and effect of BTZ alone and PEGAuNPs-BTZ on the growth inhibition (GI50) on the pancreatic cell lines S2-013, hTERT-HPNE and A549. PEGAuNPs-BTZ: Conjugated pegylated gold nanoparticles with Bortezomib BTZ: Bortezomib
